Phase 2 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 to 75 years (inclusive) who have been diagnosed with Systemic Lupus Erythematosus (SLE, a chronic autoimmune disease) based on recognised international classification standards.
- People whose blood tests show certain markers of lupus activity — specifically, a positive ANA test at a certain level, or raised levels of anti-dsDNA or anti-Sm antibodies, as measured by a central laboratory.
- People who have active lupus affecting the kidneys (called lupus nephritis) without signs of significant long-term damage, or who have active lupus affecting other parts of the body.
- People whose lupus activity score (called SLEDAI-2K) is 6 points or higher at the screening stage, not counting points related to fever, headache, hair loss, or certain brain-related symptoms.
- People whose lupus has not responded well enough to at least two previous treatments.
Who may not be able to join:
- People experiencing a sudden, severe lupus flare at the time of screening that requires immediate treatment beyond steroid injections, or that makes it impossible to safely stop current medications before the trial treatment.
- People whose organs (such as the kidneys, liver, or heart) are not functioning well enough during the screening period.
- People with a history of, or currently diagnosed with, heart rhythm or other heart problems that the trial team considers a significant safety risk.
- People who test positive for HIV at the time of screening.
- People who have an active or long-term hepatitis B or hepatitis C infection at the time of screening.
- People who have had a serious blood clot event (grade 2 or higher) within the 4 weeks before screening.
Important: Other eligibility criteria set out in the trial protocol may also apply. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Evaluate the efficacy of rapcabtagene autoleucel
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.